XML 51 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
INVESTMENTS (Tables)
 12 Months Ended
Dec. 31, 2024
Investments, All Other Investments [Abstract]  
Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):
December 31, 2024
Cost
Unrealized
Gains (Losses)
Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts
$77,551 $— $— $77,551 $77,551 $— 
Level 1:
Money market accounts13,377 — — 13,377 13,377 — 
Government & agency securities28,920 15 96 29,031 — 29,031 
Equity securities
10,000 (3,939)— 6,061 — 6,061 
52,297 (3,924)96 48,469 13,377 35,092 
Level 2:
Corporate bonds
35,771 227 326 36,324 — 36,324 
Total$165,619 $(3,697)$422 $162,344 $90,928 $71,416 
December 31, 2023
Cost
Unrealized
Gains (Losses)
Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts
$88,778 $— $— $88,778 $88,778 $— 
Level 1:
Money market accounts5,662 — — 5,662 5,662 — 
Government & agency securities15,282 126 40 15,448 — 15,448 
Equity securities
10,000 150 — 10,150 — 10,150 
30,944 276 40 31,260 5,662 25,598 
Level 2:
Corporate bonds
29,440 293 270 30,003 — 30,003 
Total$149,162 $569 $310 $150,041 $94,440 $55,601 
Summary of Investment Gains The losses related to the Company’s LifeMD investment for the year ended December 31, 2024, 2023, and 2022 are summarized in the table below (in thousands):
Twelve months ended December 31,
202420232022
Net (losses) gains recognized during the period on equity securities
$(4,089)$150 $— 
Less: Net gains (losses) recognized on equity securities sold
— — — 
Unrealized (losses) gains recognized during the reporting period on equity securities still held at the reporting date
$(4,089)$150 $—